Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Navigating CAR-T cell therapy long-term complications

Nature Cancer volume 5, pages 1768–1770 (2024)Cite this article

Subjects

Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of hematological malignancies; however long-term safety concerns, associated with infections and secondary malignancies, have been reported. Here we discuss the clinical challenges of CAR-T cell therapy in light of this emerging benefit–risk controversy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Factors that contribute to the NRM after CAR-T cell therapy and strategies for mitigation.

References

  1. Cordas Dos Santos, D. M. Nat. Med. 30, 2667–2678 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Tix, T. et al. Clin. Cancer Res. 30, 4690–4700 (2024).

    Article  PubMed  Google Scholar 

  3. Hamilton, M. P. et al. N. Engl. J. Med. 390, 2047–2060 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ozdemirli, M. et al. N. Engl. J. Med. 390, 2074–2082 (2024).

    Article  CAS  PubMed  Google Scholar 

  5. Harrison, S. J. et al. Blood 142, 6939 (2023).

    Article  Google Scholar 

  6. Berning, P. et al. Blood Cancer J. 14, 106 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Garderet, L. et al. Am. J. Hematol. 99, 2084–2095 (2024).

    Article  CAS  PubMed  Google Scholar 

  8. Shadman, M. et al. Blood Cancer J. 14, 108 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rejeski, K. Blood Adv. 8, 1857–1868 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rejeski, K. et al. J. Immunother. Cancer 10, e004475 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Panagiota, V. et al. Hemasphere 7, e957 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ghilardi, G. et al. Nat. Med. 30, 984–989 (2024).

    Article  CAS  PubMed  Google Scholar 

  13. Fraietta, J. A. et al. Nature 558, 307–312 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shah, N. N. et al. Blood Adv. 3, 2317–2322 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Micklethwaite, K. P. et al. Blood 138, 1391–1405 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for ImmunoTherapy & Precision Immuno-Oncology (CITI), Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

    Céline Grégoire & J. Joseph Melenhorst

Authors
  1. Céline Grégoire
    View author publications

    Search author on:PubMed Google Scholar

  2. J. Joseph Melenhorst
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to J. Joseph Melenhorst.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grégoire, C., Melenhorst, J.J. Navigating CAR-T cell therapy long-term complications. Nat Cancer 5, 1768–1770 (2024). https://doi.org/10.1038/s43018-024-00867-1

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-024-00867-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research